Cannabigerol is a compound from cannabis that does not cause intoxication and is sold as a dietary supplement. It is often marketed as an anti-inflammatory agent. A new laboratory study published in the journal Toxicology showed that the substance's effects on the brain's immune cells are not uniform and depend strongly on concentration.
Cannabigerol belongs to the phytocannabinoids - molecules produced by the cannabis plant. Unlike tetrahydrocannabinol, the main component responsible for intoxication, it does not impair coordination. An earlier placebo-controlled study showed that taking the supplement reduced anxiety and stress and slightly improved verbal memory in adults.
Scientists were testing whether cannabigerol can protect the nervous system from neuroinflammation - a persistent immune response in the brain and spinal cord associated with neurodegenerative diseases. Immunity in the brain is managed by microglia - cells that clear cellular debris and protect against microbes. When activated for too long, they release aggressive molecules that damage neighboring neurons.
A group led by Julia Mayara dos Santos of the University of Sao Paulo studied cannabigerol on a culture of mouse microglial cells. The cells were exposed to the substance for 24 hours at five concentrations - from 0.01 to 100 micromolar (micromolar - micromole per liter).
Doses up to and including 10 micromolar caused no noticeable cell death and slightly reduced the level of nitric oxide - a signaling gas that, when it accumulates, promotes inflammation. At 100 micromolar, survival fell to about one fifth of the control, and oxidative stress rose sharply. The cells lost their usual branched shape and became rounded.
Genetic tests produced contradictory results. When purified DNA in solution was mixed directly with cannabigerol, any concentration above 0.01 micromolar caused strand breaks. But in whole human leukocytes, no statistically significant differences in DNA damage compared with the control were found. The authors suggest that living cells protect their DNA with antioxidant systems, detoxification of the substance, and repair enzymes.
In experiments with artificially induced inflammation, cannabigerol partially restored microglial survival but did not reduce the surge of reactive oxygen species. The effect on nitric oxide depended on the dose. At a concentration of 0.01 micromolar, cannabigerol did not suppress but rather increased the expression of the Caspase-1 gene - an enzyme involved in the inflammatory response - to about 375% of the level in control cells.
According to the authors, such results do not allow cannabigerol to be considered a simple anti-inflammatory agent. Independent expert Daniele Piomelli of the University of California, Irvine, noted that the study was performed on a single cell line, and that the effect sizes are modest and the therapeutic window is narrow - the difference between the beneficial and toxic dose is small.
Limitations should be taken into account: the mouse cell line used differs from primary microglia from living tissue, and experiments in plastic dishes do not reproduce the conditions of the body. The survival test assessed the activity of mitochondrial enzymes rather than directly counting dead cells, and Caspase-1 was measured only by messenger RNA at a single low concentration. The authors conclude that experiments on primary cultures, three-dimensional tissue models, and animals are needed to understand the real risks and benefits.